| 1 |
31213849 | Knockdown of cyclooxygenase-2 leads to growth inhibition and cell cycle arrest in hepatocellular carcinoma cells. | 2019 |
2 |
| 2 |
28750089 | A synthetic cationic antimicrobial peptide inhibits inflammatory response and the NLRP3 inflammasome by neutralizing LPS and ATP. | 2017 |
2 |
| 3 |
26556718 | Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma. | 2015 |
2 |
| 4 |
25222785 | Dipyrone & 2,5-dimethylcelecoxib suppress Th2-related chemokine production in monocyte. | 2014 Jul |
2 |
| 5 |
24505512 | Cyclooxygenase-2 expression in lymphoma in north-west of iran. | 2013 |
1 |
| 6 |
22331023 | The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. | 2012 May |
3 |
| 7 |
19422084 | Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. | 2009 May |
2 |
| 8 |
18242145 | Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. | 2008 May |
1 |
| 9 |
17222364 | [Effects of COX-2 gene silencing by shRNA on biological characteristics of human hepatocellular carcinoma cell line HepG2]. | 2007 Jan |
2 |
| 10 |
17430655 | [Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24]. | 2007 Apr |
3 |
| 11 |
17556027 | Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. | 2007 Jul |
1 |
| 12 |
17631131 | Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. | 2007 Jul |
1 |
| 13 |
17672932 | [Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]. | 2007 May |
2 |
| 14 |
16996805 | Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. | 2006 Nov |
1 |
| 15 |
15694043 | [Expressions of cyclooxygenase-2 and cholecystokinin-B receptor mRNA in human colonic cancer and their significances]. | 2005 Feb |
2 |
| 16 |
15704047 | Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. | 2005 Feb |
1 |
| 17 |
16552960 | [Expression of cyclooxygenase-2 and inducible nitric oxide synthase in tongue hyperplasia and tongue squamous cell carcinoma]. | 2005 Nov |
2 |
| 18 |
15300574 | Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. | 2004 Aug |
2 |
| 19 |
15319795 | Etoricoxib. | 2004 May |
2 |
| 20 |
15473933 | [Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer]. | 2004 Oct |
1 |
| 21 |
15601550 | [Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR]. | 2004 Dec |
2 |
| 22 |
12891540 | Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. | 2003 Aug |
2 |
| 23 |
12948419 | [Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas]. | 2003 Jun |
1 |
| 24 |
12949718 | The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. | 2003 Sep |
2 |
| 25 |
11375952 | Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. | 2001 Jun |
2 |